Mihir Khunte

Mihir Khunte

Auto-generated profile, based on publicly available information

Mihir Khunte

Department of Radiology and Biomedical Imaging, Yale School of Medicine

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2022 in Radiology
Verified
Journal Article
Closed access
XWXiao Wu
Xiao Wu
SBSuryansh Bajaj
Suryansh Bajaj
MKMihir Khunte
Mihir Khunte
MRMargarita Revzin
Margarita Revzin
DGDheeraj Gandhi
Dheeraj Gandhi
AMAjay Malhotra
Ajay Malhotra
Identifying reasons for the low proportion of female and underrepresented minority radiology residency applicants, despite a highly diverse pool of medical students, would be key to increasing thei... Background There have been growing efforts nationally and institutionally toward diversity in radiology. Purpose To analyze sex and racial and ethnic diversity over time (2010–2019) for the various...

1 October 2024 in Radiology
Verified
Journal Article
Closed access
AMAjay Malhotra
Ajay Malhotra
DFDheeman Futela
Dheeman Futela
RJRudra Joshi
Rudra Joshi
MKMihir Khunte
Mihir Khunte
NMNagaraj S. Moily
Nagaraj S. Moily
DGDheeraj Gandhi
Dheeraj Gandhi
Salary inequities persist in academic radiology and should be addressed as part of the broader drive to increase diversity, equity, and inclusion.

1 June 2025 in Stroke
Verified
Journal Article
Closed access
HCHuanwen Chen
Huanwen Chen
MKMihir Khunte
Mihir Khunte
MCMarco Colasurdo
Marco Colasurdo
AMAjay Malhotra
Ajay Malhotra
DGDheeraj Gandhi
Dheeraj Gandhi
BACKGROUND: Recent randomized control trials have demonstrated the efficacy and safety of middle meningeal artery embolization (MMAE) as an adjunct to conventional management for patients with nonacute subdural hematoma (SDH); however, a large majority of trial participants received surgical evacuation as part of the standard of care. Thus, the efficacy and safety of standalone MMAE compared with conservative management (CM) for patients with nonsurgical SDH are unclear. METHODS: This was a retrospective cohort study of the 2019 to 2021 Nationwide Readmissions Database in the United States. Patients with nonsurgical nontraumatic SDH were identified, and MMAE patients were matched with similar CM patients using propensity scores calculated from demographics, comorbidities, and initial hospitalization outcomes. Patients were followed up to 300 days. The primary end point was composite surgical rescue or death, and secondary end points included surgical rescue and all-cause mortality by 180 days. RESULTS: A total of 24 465 patients with nonsurgical nontraumatic SDH were identified; 2228 (9.1%) underwent MMAE. After propensity score matching, 6675 patients remained in the CM group and 2217 in the MMAE group. At 180 days, MMAE patients had a significantly lower risk of surgery or death compared with CM (8.2% versus 10.9%; relative risk, 0.75 [95% CI, 0.59–0.96]; P =0.022) and lower risk of death (1.1% versus 3.0%; relative risk, 0.38 [95% CI, 0.17–0.86]; P =0.020). Rates of surgical rescue among MMAE and CM patients at 180 days were similar (7.1% versus 8.4%; relative risk, 0.85 [95% CI, 0.63–1.14]; P =0.27). Time-to-event analyses for the entire 300-day study follow-up period confirmed that while MMAE was associated with a lower cumulative risk of all-cause mortality (hazard ratio, 0.55 [95% CI, 0.35–0.87]; P =0.010), it was not associated with a different risk of surgical rescue (hazard ratio, 1.00 [95% CI, 0.76–1.31]; P =1.00). CONCLUSIONS: Standalone MMAE may be beneficial for patients with nonsurgical nontraumatic SDH by reducing the long-term risk of all-cause mortality.

1 February 2023 in Stroke
Verified
Journal Article
Closed access
PDF file
HCHuanwen Chen
Huanwen Chen
MKMihir Khunte
Mihir Khunte
MCMarco Colasurdo
Marco Colasurdo
GJGaurav Jindal
Gaurav Jindal
AMAjay Malhotra
Ajay Malhotra
SCSeemant Chaturvedi
Seemant Chaturvedi
Background: Osteoarthritis and other musculoskeletal disorders are the leading causes of disability in the United States. While osteoarthritis is not a direct risk factor for stroke, osteoarthritis may impact patient selection for endovascular thrombectomy (EVT) due to prestroke disability. This study investigates associations of osteoarthritis with EVT utilization and outcomes. Methods: This was a large-scale cross-sectional study of the 2016 to 2019 National Inpatient Sample database. Adult patients with anterior large vessel ischemic strokes were identified. Patient demographics, stroke risk factors, stroke etiology, presence of osteoarthritis, medical comorbidities, EVT, intravenous thrombolysis treatments, and discharge destinations were recorded. Primary outcome was the rate of EVT treatment. Secondary outcomes include rates of discharge to home and in-hospital mortality. Propensity score matching and multivariable logistic regression models were used to account for possible confounders. Results: Two hundred fifty-two thousand five hundred five patients were identified, of whom 8.5% (21 500 patients) had osteoarthritis. After propensity score matching for 32 clinical variables, osteoarthritis patients were found to be 17.3% less likely to receive EVT than non-osteoarthritis patients (14.4% versus 17.3%, respectively; P <0.001). In multivariable logistic regression analysis, osteoarthritis was associated with 22.6% lower odds of receiving EVT (OR, 0.77 [95% CI, 0.70–0.86]; P <0.001), an effect size larger than any medical comorbidity captured in this study other than dementia and nonstroke neurological disease. Among those treated with EVT, multivariable logistic regression models showed that osteoarthritis was not associated with different odds of being discharged home (OR, 0.99 [95% CI, 0.81–1.21]; P =0.93); however, osteoarthritis was marginally associated with lower odds of in-hospital mortality (OR, 0.74 [95% CI, 0.54–1.01]; P =0.054). Conclusions: Large vessel ischemic stroke patients with osteoarthritis were significantly less likely to receive EVT therapy despite similar post-EVT outcomes. These results warrant further investigation and prompt a critical review of current patient selection practices for stroke EVT therapy, specifically for patients with baseline disability due to musculoskeletal conditions such as osteoarthritis.

10 November 2023 in Clinical Imaging
Verified
Journal Article
Closed access
XWXiao Wu
Xiao Wu
MKMihir Khunte
Mihir Khunte
KTKyle Tegtmeyer
Kyle Tegtmeyer
SBSuryansh Bajaj
Suryansh Bajaj
PPPriyanka Prajapati
Priyanka Prajapati
AMAjay Malhotra
Ajay Malhotra

25 August 2024 in Diagnostics
Verified
Journal Article
Open access
PDF file
HCHuanwen Chen
Huanwen Chen
MCMarco Colasurdo
Marco Colasurdo
MKMihir Khunte
Mihir Khunte
AMAjay Malhotra
Ajay Malhotra
DGDheeraj Gandhi
Dheeraj Gandhi
Background: Subarachnoid hemorrhage (SAH) following endovascular thrombectomy (EVT) is a poorly understood phenomenon, and whether it is associated with clinical detriment is unclear. Methods: This was an explorative analysis of a national database of real-world hospitalizations in the United States. Patients who underwent EVT were included. Patients were divided into SAH and non-SAH groups, and hospitalization outcomes were compared using multivariable logistic regression models. Regression models were also used to identify significant predictors for post-EVT SAH, and significant modulators of SAH’s association with hospitalization outcomes were also assessed. Results: A total of 99,219 EVT patients were identified; 6174 (6.2%) had SAH. Overall, SAH was independently associated with increased odds of in-hospital mortality (21.5% vs. 10.6%, adjusted OR 2.53 [95%CI 2.23–2.87], p < 0.001) and lower odds of routine discharge to home with self-care (18.2% vs. 28.0%, aOR 0.58 [95%CI 0.52–0.65], p < 0.001). Distal/medium vessel occlusion (DMVO), coagulopathy, angioplasty or stenting, concurrent intraparenchymal hemorrhage (IPH), and female sex were associated with higher odds of SAH. DMVO was associated with particularly heightened risk of death (31.8% vs. 7.9%, aOR 6.99 [95%CI 2.99 to 16.3], p < 0.001), which was an effect size significantly larger than other sites of vascular occlusion (interaction p > 0.05). Conclusion: SAH is an uncommon but likely clinically detrimental post-EVT complication. DMVO, coagulopathy, angioplasty or stenting, concurrent IPH, and female sex were independently associated with higher odds of post-EVT SAH. SAH associated with DMVO-EVT may be particularly harmful.